# A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

> **NCT04909034** · NA · COMPLETED · sponsor: **Microbio Co Ltd** · enrollment: 15 (actual)

## Conditions studied

- NSCLC Stage IIIB~IV

## Interventions

- **DRUG:** MS-20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04909034
- **Lead sponsor:** Microbio Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-20
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-11-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909034, "A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04909034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*